We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+23.29%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.39B
AUM Growth
+$47.2M
(+2%)
Cap. Flow
-$369M
Cap. Flow
% of AUM
-15.45%
Top 10 Holdings %
Top 10 Hldgs %
46.51%
Holding
68
New
22
Increased
12
Reduced
15
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$125M |
| 2 |
Cigna
CI
|
+$89.6M |
| 3 |
AbbVie
ABBV
|
+$75.2M |
| 4 |
Danaher
DHR
|
+$61M |
| 5 |
HCA Healthcare
HCA
|
+$59.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Haemonetics
HAE
|
+$143M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$132M |
| 3 |
Teleflex
TFX
|
+$119M |
| 4 |
Labcorp
LH
|
+$84.7M |
| 5 |
NVRO
NEVRO CORP.
NVRO
|
+$82.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.83% |
| 2 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Agios Pharmaceuticals
AGIO
$1.9B
| – | – |
-408,844
| Closed | -$14.5M |
|
|
AMRN
52
Amarin Corp
AMRN
$303M
| – | – |
-381,858
| Closed | -$30.5M |
|
53
Bausch Health
BHC
$2.29B
| – | – |
-3,819,630
| Closed | -$59.2M |
|
54
Biogen
BIIB
$30.4B
| – | – |
-48,002
| Closed | -$15.2M |
|
55
CONMED
CNMD
$1.46B
| – | – |
-687,466
| Closed | -$39.4M |
|
56
CVS Health
CVS
$122B
| – | – |
-1,234,120
| Closed | -$73.2M |
|
|
57
Haemonetics
HAE
$3.91B
| – | – |
-1,438,356
| Closed | -$143M |
|
|
HOLX
58
DELISTED
Hologic
HOLX
| – | – |
-625,240
| Closed | -$21.9M |
|
59
Envista
NVST
$4.52B
| – | – |
-888,210
| Closed | -$13.3M |
|
60
Omega Healthcare
OHI
$14.7B
| – | – |
-2,038,390
| Closed | -$54.1M |
|
61
Rocket Pharmaceuticals
RCKT
$380M
| – | – |
-369,639
| Closed | -$5.16M |
|
62
Teva Pharmaceuticals
TEVA
$40.9B
| – | – |
-1,492,800
| Closed | -$13.4M |
|
|
63
Teleflex
TFX
$6.02B
| – | – |
-406,930
| Closed | -$119M |
|
64
Welltower
WELL
$170B
| – | – |
-1,582,360
| Closed | -$72.4M |
|
65
State Street SPDR S&P Biotech ETF
XBI
$10.1B
| – | – |
-196,850
| Closed | -$15.2M |
|
66
Zymeworks
ZYME
$1.74B
| – | – |
-416,700
| Closed | -$14.8M |
|
|
PTE
67
DELISTED
PolarityTE, Inc. Common Stock
PTE
| – | – |
-25,444
| Closed | -$687K |
|
|
ALXN
68
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
| – | – |
-150,000
| Closed | -$13.5M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q2 2020 Portfolio in Review
As of Q2 2020, HealthCor Management held 68 positions worth $2.39B, up 2% from $2.34B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
HealthCor Management withdrew a net $369M in Q2 2020, closing 18 positions and reducing 15 holdings. Its most notable exit was Haemonetics, an estimated $143M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 93% a quarter earlier, followed by Real Estate.
Against the trend, HealthCor Management opened a new position in Cigna worth $88.6M.
- HealthCor Management's largest Q2 2020 buy was Cigna: 472,360 shares worth $88.6M.
- HealthCor Management added most to Becton Dickinson in Q2 2020, an estimated $125M increase.
- HealthCor Management's biggest Q2 2020 reduction was Neurocrine Biosciences, cutting an estimated $132M.
- HealthCor Management fully exited Haemonetics in Q2 2020, selling an estimated $143M.
- HealthCor Management's ten largest holdings make up 47% of its $2.39B portfolio in Q2 2020.
- HealthCor Management opened 22 new positions and closed 18 in Q2 2020.
- HealthCor Management's portfolio value rose 2% quarter-over-quarter to $2.39B.
Based on HealthCor Management's 13F filing for Q2 2020, filed 14 Aug 2020.